National award recognizes Castle’s strong culture and employee engagement Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health...
The study, published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus (BE) patients with an initial...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the...
IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates the results of drug-gene interactions with drug-drug...
The TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share a poster...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek...
In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for...
Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.